The Phase 3 ECLIPSE 1 data support a potential regulatory filing for elebsiran + tobevibart in chronic hepatitis delta. Monitor the upcoming investor call for details on the regulatory pathway and commercialization timeline. The SOLSTICE finite treatment data, while early, suggest potential for a functional cure, which would be transformative if confirmed in larger studies.
Drugs in focus
VIR drug pipeline →elebsiran
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 ECLIPSE 1 results are positive, regulatory filings could follow in 2027, with potential FDA approval in 2027-2028 given the Breakthrough Therapy designation enabling expedited review.
- Next catalyst
- None dated
What to watchThe pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $13.65entry
- T+1 · 7d ago −3.63%α −3.26% · $13.15
- T+5 · 17h ago −29.79%α −28.10% · $9.58
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology announced positive Phase 3 ECLIPSE 1 topline results for its combination regimen of elebsiran and tobevibart in chronic hepatitis delta, meeting the primary endpoint with a 44% response rate vs 0% in the delayed treatment group (p<0.0001). Expanded Phase 2 SOLSTICE data showed 100% of patients reaching undetectable viremia at Week 96, and an exploratory finite treatment analysis showed all 10 patients who discontinued treatment achieved SVR12. The data were presented at AASLD on November 8, 2026.
Key Facts
- Phase 3 ECLIPSE 1 primary endpoint met: 44% undetectable virus + ALT normalization at Week 48 vs 0% in delayed treatment group (p<0.0001)
- Key secondary endpoint: 79% undetectable virus at Week 48 vs 0% (p<0.0001)
- 100% virologic response (HDV RNA TND or 2 log10 reduction) in active arm vs 0% in control
- Phase 2 SOLSTICE Week 96: 100% (28/28) of patients on combination therapy reached undetectable viremia
- Exploratory finite treatment analysis: all 10 patients who discontinued achieved SVR12, 7 achieved SVR24, 1 achieved SVR48
- Regimen well-tolerated: one Grade 3 TRAE (neutrophil count decrease, resolved in 15 days), no treatment discontinuations
- Trial enrolled 124 patients randomized 2:1, including patients with advanced disease and cirrhosis
Financial Impact
Positive Phase 3 data in chronic hepatitis delta, a disease with no approved therapies, could unlock a significant commercial opportunity; market cap is $1.9B
Risk Factors
- SOLSTICE finite treatment data are preliminary, based on only 10 patients, and have not undergone formal data cut; results may not be representative
- Regulatory approval is not guaranteed; the FDA may require additional trials or longer follow-up data
- Commercialization in chronic hepatitis delta faces challenges including patient identification, market access, and potential competition from other investigational therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-071908 |
| Document: 0001628280-26-071908-index-headers.html | 0001628280-26-071908 |
| Document: 0001628280-26-071908-index.html | 0001628280-26-071908 |
| Document: 0001628280-26-071908.txt | 0001628280-26-071908 |
Track record
36 reports on VIR
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers